C Winkelmann

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

Stefan Boeck, Andreas Jung, Rüdiger P. Laubender et al. · British Journal of Cancer · 2012 · 117 citations · Full text

Medicine, Oncology, Pharmacology +17

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)

Michael Herold, Antina Schulze, Dietger Niederwieser et al. · Journal of Cancer Research and Clinical Oncology · 2005 · 103 citations · Full text

Medicine, Oncology, Pharmacology +14

Gemcitabine plus erlotinib (GE) followed by capecitabine (C) versus capecitabine plus erlotinib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): A randomized, cross-over phase III trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Stefan Boeck, U. Vehling-Kaiser, Dirk Waldschmidt et al. · Journal of Clinical Oncology · 2010 · 17 citations

Medicine, Oncology, Pharmacology +12